2:I[6146,[],""]
3:I[4411,[],""]
4:"$Sreact.suspense"
5:I[7256,["863","static/chunks/863-822c2cde35e02348.js","185","static/chunks/app/layout-fb78cfc571d4c3d6.js"],"KeyboardNavigation"]
6:I[5407,["863","static/chunks/863-822c2cde35e02348.js","185","static/chunks/app/layout-fb78cfc571d4c3d6.js"],"SlideNavigation"]
0:["DkpgZd6XOJjDaY981EGFp",[[["",{"children":["pages",{"children":["3",{"children":["__PAGE__",{}]}]}]},"$undefined","$undefined",true],["",{"children":["pages",{"children":["3",{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"relative overflow-hidden w-[1920px] h-[1080px] bg-gradient-to-br from-slate-900 to-slate-700 text-white","children":["$","div",null,{"className":"flex flex-col w-full h-full","children":[["$","div",null,{"className":"flex-none bg-slate-800/90 p-6 flex items-center gap-4","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":48,"height":48,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-building2 text-blue-400","children":[["$","path","1b4qmf",{"d":"M6 22V4a2 2 0 0 1 2-2h8a2 2 0 0 1 2 2v18Z"}],["$","path","i71pzd",{"d":"M6 12H4a2 2 0 0 0-2 2v6a2 2 0 0 0 2 2h2"}],["$","path","10jefs",{"d":"M18 9h2a2 2 0 0 1 2 2v9a2 2 0 0 1-2 2h-2"}],["$","path","1itunk",{"d":"M10 6h4"}],["$","path","tcdvrf",{"d":"M10 10h4"}],["$","path","kelpxr",{"d":"M10 14h4"}],["$","path","1ulq68",{"d":"M10 18h4"}],"$undefined"]}],["$","h1",null,{"className":"text-6xl font-bold text-white","children":"Company & Product Overview"}]]}],["$","div",null,{"className":"flex-1 min-h-0 grid grid-cols-[2fr_3fr] gap-8 p-8","children":[["$","div",null,{"className":"flex flex-col gap-6","children":[["$","div",null,{"className":"bg-slate-800/85 p-6 rounded-lg","children":[["$","h3",null,{"className":"text-4xl font-bold text-white mb-6","children":"Corporate Evolution"}],["$","div",null,{"className":"space-y-4","children":[["$","div",null,{"className":"flex items-center gap-4","children":[["$","div",null,{"className":"w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center","children":["$","p",null,{"className":"text-xl font-bold","children":"2014"}]}],["$","p",null,{"className":"text-2xl","children":"Checkpoint Therapeutics founded by Fortress Biotech"}]]}],["$","div",null,{"className":"ml-8 w-0.5 h-8 bg-blue-400"}],["$","div",null,{"className":"flex items-center gap-4","children":[["$","div",null,{"className":"w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center","children":["$","p",null,{"className":"text-lg font-bold","children":"Dec 2024"}]}],["$","p",null,{"className":"text-2xl","children":"Unloxcyt FDA approval for advanced cSCC"}]]}],["$","div",null,{"className":"ml-8 w-0.5 h-8 bg-blue-400"}],["$","div",null,{"className":"flex items-center gap-4","children":[["$","div",null,{"className":"w-16 h-16 bg-purple-500 rounded-full flex items-center justify-center","children":["$","p",null,{"className":"text-lg font-bold","children":"May 2025"}]}],["$","p",null,{"className":"text-2xl","children":"Sun Pharma acquisition ($416M total value)"}]]}]]}],["$","p",null,{"className":"text-xl text-gray-300 mt-6","children":[["$","strong",null,{"children":"Headquarters:"}]," Waltham, Massachusetts, USA"]}]]}],["$","div",null,{"className":"bg-slate-800/85 p-6 rounded-lg","children":[["$","h3",null,{"className":"text-4xl font-bold text-orange-400 mb-6","children":"Acquisition Structure"}],["$","div",null,{"className":"space-y-3","children":[["$","div",null,{"className":"flex justify-between","children":[["$","p",null,{"className":"text-2xl text-gray-300","children":"Upfront Cash:"}],["$","p",null,{"className":"text-2xl font-bold","children":"$$355M ($4.10/share)"}]]}],["$","div",null,{"className":"flex justify-between","children":[["$","p",null,{"className":"text-2xl text-gray-300","children":"Contingent CVR:"}],["$","p",null,{"className":"text-2xl font-bold","children":"Up to $4.8M (EU approvals)"}]]}],["$","div",null,{"className":"flex justify-between","children":[["$","p",null,{"className":"text-2xl text-gray-300","children":"Fortress Royalty:"}],["$","p",null,{"className":"text-2xl font-bold","children":"2.5% on net sales"}]]}]]}],["$","p",null,{"className":"text-xl text-gray-300 italic mt-4","children":"Sun Pharma gains specialty oncology-dermatology asset with global commercialization infrastructure"}]]}]]}],["$","div",null,{"className":"bg-slate-800/85 p-6 rounded-lg","children":[["$","h2",null,{"className":"text-5xl font-bold bg-gradient-to-r from-blue-400 to-purple-400 bg-clip-text text-transparent mb-2","children":"Unloxcyt (cosibelimab-ipdl)"}],["$","h3",null,{"className":"text-3xl text-green-400 mb-8","children":"First and Only FDA-Approved PD-L1 Inhibitor for Advanced cSCC"}],["$","h4",null,{"className":"text-4xl font-bold text-white mb-4","children":"Mechanism of Action"}],["$","div",null,{"className":"space-y-3 mb-8","children":[["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":20,"height":20,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-blue-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Human IgG1 monoclonal antibody targeting PD-L1"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":20,"height":20,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-blue-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Dual action: Blocks PD-L1/PD-1 and PD-L1/B7.1 interactions"}]]}],["$","div",null,{"className":"flex items-start gap-3","children":[["$","svg",null,{"xmlns":"http://www.w3.org/2000/svg","width":20,"height":20,"viewBox":"0 0 24 24","fill":"none","stroke":"currentColor","strokeWidth":2,"strokeLinecap":"round","strokeLinejoin":"round","className":"lucide lucide-circle-check-big text-blue-400 mt-1","children":[["$","path","yps3ct",{"d":"M21.801 10A10 10 0 1 1 17 3.335"}],["$","path","1pflzl",{"d":"m9 11 3 3L22 4"}],"$undefined"]}],["$","p",null,{"className":"text-2xl","children":"Induces antibody-dependent cell-mediated cytotoxicity (ADCC)"}]]}]]}],["$","h4",null,{"className":"text-4xl font-bold text-white mb-4","children":"Clinical Efficacy (Study CK-301-101)"}],["$","div",null,{"className":"grid grid-cols-2 gap-4 mb-8","children":[["$","div",null,{"className":"bg-slate-700/50 p-4 rounded-lg","children":[["$","p",null,{"className":"text-xl text-gray-300","children":"Metastatic cSCC ORR"}],["$","p",null,{"className":"text-3xl font-bold text-green-400","children":"47%"}]]}],["$","div",null,{"className":"bg-slate-700/50 p-4 rounded-lg","children":[["$","p",null,{"className":"text-xl text-gray-300","children":"Locally Advanced ORR"}],["$","p",null,{"className":"text-3xl font-bold text-green-400","children":"48%"}]]}],["$","div",null,{"className":"bg-slate-700/50 p-4 rounded-lg","children":[["$","p",null,{"className":"text-xl text-gray-300","children":"Median Duration (Met)"}],["$","p",null,{"className":"text-2xl font-bold text-green-400","children":"Not reached"}]]}],["$","div",null,{"className":"bg-slate-700/50 p-4 rounded-lg","children":[["$","p",null,{"className":"text-xl text-gray-300","children":"12-Month Response"}],["$","p",null,{"className":"text-2xl font-bold text-green-400","children":"75.4% / 88.2%"}]]}]]}],["$","div",null,{"className":"space-y-4","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-2xl font-bold text-white mb-2","children":"Indication:"}],["$","p",null,{"className":"text-xl text-gray-300","children":"Metastatic or locally advanced cutaneous squamous cell carcinoma in adults not candidates for curative surgery or radiation"}]]}],["$","div",null,{"children":[["$","p",null,{"className":"text-2xl font-bold text-white mb-2","children":"Dosing:"}],["$","p",null,{"className":"text-xl text-gray-300","children":"1,200 mg IV infusion every 3 weeks"}]]}]]}]]}]]}],["$","div",null,{"className":"flex-none p-4 text-right","children":["$","p",null,{"className":"text-xl text-gray-400","children":"3"}]}]]}]}],null],null],null]},[null,["$","$L2",null,{"parallelRouterKey":"children","segmentPath":["children","pages","children","3","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L3",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined"}]],null]},[null,["$","$L2",null,{"parallelRouterKey":"children","segmentPath":["children","pages","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L3",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined"}]],null]},[[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/8d323862949ffad9.css","precedence":"next","crossOrigin":"$undefined"}]],["$","html",null,{"lang":"en","className":"dark","children":["$","body",null,{"className":"__className_f367f3 h-1080px w-1920px","children":[["$","$4",null,{"fallback":null,"children":[["$","$L5",null,{}],["$","$L6",null,{}]]}],["$","$L2",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L3",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":[["$","title",null,{"children":"404: This page could not be found."}],["$","div",null,{"style":{"fontFamily":"system-ui,\"Segoe UI\",Roboto,Helvetica,Arial,sans-serif,\"Apple Color Emoji\",\"Segoe UI Emoji\"","height":"100vh","textAlign":"center","display":"flex","flexDirection":"column","alignItems":"center","justifyContent":"center"},"children":["$","div",null,{"children":[["$","style",null,{"dangerouslySetInnerHTML":{"__html":"body{color:#000;background:#fff;margin:0}.next-error-h1{border-right:1px solid rgba(0,0,0,.3)}@media (prefers-color-scheme:dark){body{color:#fff;background:#000}.next-error-h1{border-right:1px solid rgba(255,255,255,.3)}}"}}],["$","h1",null,{"className":"next-error-h1","style":{"display":"inline-block","margin":"0 20px 0 0","padding":"0 23px 0 0","fontSize":24,"fontWeight":500,"verticalAlign":"top","lineHeight":"49px"},"children":"404"}],["$","div",null,{"style":{"display":"inline-block"},"children":["$","h2",null,{"style":{"fontSize":14,"fontWeight":400,"lineHeight":"49px","margin":0},"children":"This page could not be found."}]}]]}]}]],"notFoundStyles":[]}]]}]}]],null],null],["$L7",null]]]]
7:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"Unloxcyt Market Survey - Interactive Presentation"}],["$","meta","3",{"name":"description","content":"Comprehensive market analysis of Cosibelimab-ipdl for advanced cSCC"}],["$","meta","4",{"name":"next-size-adjust"}]]
1:null
